Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	65832
Country	China

Received	2021-03-17 03:49
Peer-Review Started	2021-03-17 04:26
To Make the First Decision
Return for Revision	2021-07-28 13:56
Revised	2021-08-11 15:26
Second Decision	2021-11-30 03:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-11-30 19:15
Articles in Press	2021-11-30 19:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-12-31 04:20
Publish the Manuscript Online	2022-01-11 00:11

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
Manuscript Source	Invited Manuscript
All Author List	Hui-Yan Sun, Song-Tao Du, Ya-Yun Li, Guang-Tong Deng and Fu-Rong Zeng
ORCID	Author(s) ORCID Number Hui-Yan Sun http://orcid.org/0000-0002-5697-933X Song-Tao Du http://orcid.org/0000-0001-5536-3632 Ya-Yun Li http://orcid.org/0000-0002-4799-663X Guang-Tong Deng http://orcid.org/0000-0002-4424-9727 Fu-Rong Zeng http://orcid.org/0000-0001-6621-8131
Funding Agency and Grant Number	Funding Agency Grant Number Fellowship of the China Postdoctoral Science Foundation 2020M682594 Fellowship of the China Postdoctoral Science Foundation 2021T140748
Corresponding Author	Fu-Rong Zeng, MD, Doctor, Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. zengflorachn@hotmail.com
Key Words	Gastrointestinal cancer; Bromodomain and extra-terminal proteins; Bromodomain and extra-terminal inhibitors; Acetylated lysines
Core Tip	Bromodomain and extra-terminal (BET) inhibitors, as promising targeted agents, emerge as a new therapeutic avenue for gastrointestinal (GI) cancers. Based on preclinical evidence, BET inhibitors, alone or in combination with other therapies, were effective to suppress the progression of GI cancers.
Publish Date	2022-01-11 00:11
Citation	Sun HY, Du ST, Li YY, Deng GT, Zeng FR. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 75-89
URL	https://www.wjgnet.com/1948-5204/full/v14/i1/75.htm
DOI	https://dx.doi.org/10.4251/wjgo.v14.i1.75

Full Article (PDF)	WJGO-14-75.pdf
Full Article (Word)	WJGO-14-75.docx
Manuscript File	65832_Auto_Edited.docx
Answering Reviewers	65832-Answering reviewers.pdf
Audio Core Tip	65832-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	65832-Conflict-of-interest statement.pdf
Copyright License Agreement	65832-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	65832-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	65832-Language certificate.pdf
Peer-review Report	65832-Peer-review(s).pdf
Scientific Misconduct Check	65832-Bing-Fan JR-2.png
Scientific Editor Work List	65832-Scientific editor work list.pdf
CrossCheck Report	65832-CrossCheck report.pdf
CrossCheck Report	65832-CrossCheck.png